EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

Jean-Baptiste Bachet, Pierre Laurent-Puig, Aurelia Meurisse, Olivier Bouché, Léo Mas, Valérie Taly, Romain Cohen, Jean-Marc Gornet, Pascal Artru, Samy Louafi, Anne Thirot-Bidault, Isabelle Baumgaertner und 9 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.05.022 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Jean-Baptiste Bachet und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Paris, France; AGEO (Association des Gastroentérologues Oncologues), Par…. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Baseline circulating tumour DNA (ctDNA) is a potential prognostic marker in metastatic colorectal cancer (mCRC) patients. However, few studies have compared ctDNA with the usual prognostic factors, and no ctDNA cut-off has been proposed for daily use in clinical practice. PATIENTS AND METHODS: Chemotherapy-naive patients with mCRC were prospectively included. Plasma samples were collected at diagnosis and analysed centrally by both NGS and methylation digital PCR. Baseline patient and disease characteristics, treatment regimens, and secondary surgeries were collected. The restricted cubic spline method was used to define the optimal cut-off of ctDNA mutated allelic frequency (MAF). Prognostic values were assessed on overall survival (OS) using Cox models. RESULTS: From July 2015 to December 2016, 412 patients were included. ctDNA was undetectable in 83 patients (20%). ctDNA was an independent prognostic marker for OS considering the whole study population. The optimal cut-off for ctDNA MAF was 20% with median OS of 16.0 and 35.8 months for patients with MAF ≥20% and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAColonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsHumansBiomarkers, TumorMutationPrognosisProspective Studies

Stichwörter der Autor:innen

BRAFCEACirculating tumour DNAColorectal cancerMetastasesPrognostic valueRAS

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Hepato-gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Paris, France; AGEO (Association des Gastroentérologues Oncologues), Paris, France; Sorbonne Universités, UPMC Université, Paris 06, France; C…
  • Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université Paris Cité, Paris, France; Institut du cancer Paris CARPEM, AP-HP, Hopital européen Georges Pompidou, Paris, France. Electronic…
  • Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Besançon, France.
  • AGEO (Association des Gastroentérologues Oncologues), Paris, France; Department of Hepato-Gastroenterology, CHU Reims, Reims, France.
  • Department of Hepato-gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Paris, France; AGEO (Association des Gastroentérologues Oncologues), Paris, France.
  • Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université Paris Cité, Paris, France.

Zitieren

APA

Bachet, J. B., Laurent-Puig, P., Meurisse, A., Bouché, O., Mas, L., Taly, V., Cohen, R., Gornet, J. M., Artru, P., Louafi, S., Thirot-Bidault, A., Baumgaertner, I., Coriat, R., Tougeron, D., Lecomte, T., Mary, F., Aparicio, T., Marthey, L., Blons, H., …, & Taieb, J. (2023). Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.05.022

Vancouver

Bachet JB, Laurent-Puig P, Meurisse A, Bouché O, Mas L, Taly V, et al. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.05.022

BibTeX
@article{Bachet2023,
  author = {Bachet, Jean-Baptiste and Laurent-Puig, Pierre and Meurisse, Aurelia and Bouché, Olivier and Mas, Léo and Taly, Valérie and Cohen, Romain and Gornet, Jean-Marc and Artru, Pascal and Louafi, Samy and Thirot-Bidault, Anne and Baumgaertner, Isabelle and Coriat, Romain and Tougeron, David and Lecomte, Thierry and Mary, Florence and Aparicio, Thomas and Marthey, Lysiane and Blons, Hélène and Vernerey, Dewy and Taieb, Julien},
  title = {Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.05.022}
}
Kostenlos starten →